東陽光藥(01558.HK):磷酸依米他韋膠囊獲批准上市
格隆匯 12 月 28日丨東陽光藥(01558.HK)宣佈,公司自主研究及開發的產品磷酸依米他韋膠囊(0.1g)已獲中國國家藥品監督管理局審批完畢並獲准上市。
據悉,磷酸依米他韋是口服直接抗丙肝病毒藥物,非結構蛋白("NS")5A抑制劑。該藥品針對基因1型無肝硬化丙肝患者療效顯著,12周持續病毒應答率(SVR12)達99.8%,且用藥安全性及耐受性良好。
磷酸依米他韋膠囊是中國1類創新藥,根據艾美仕資料顯示,2019年國內口服抗丙肝病毒藥物銷售金額為1,300多萬美元,較2018年增長率為75.3%,具有可觀的增長潛力。
公吿稱,該產品獲批上市後,成為公司在抗丙肝治療領域的主打產品之一,具有很高的臨牀應用價值和良好的市場前景,亦有益於拓展集團抗病毒領域業務,並進一步豐富集團的產品組合,以及為廣大患者提供質價雙優的用藥選擇。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.